Moreover, it is crucial to assess whether integrating tumor budding assessment with other established prognostic markers, such as hormone receptor status and HER2 expression, could enhance the accuracy of risk stratification and personalized treatment approaches [49]. This evidence concerns the gene NR4A1 and neoplasm.